Ceftaroline fosamil: Cephalosporin antibiotic

Drugs of the Future

Volumn 33, Issue 4, 2008, Pages 302-309

  Wang, Y ^a   Mealy, N ^b  

^a IBC   (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; DAPTOMYCIN; HABEKACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2; PENICILLIN G; PPI 0903; PPI 0903M; T 91825; TAK 599; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENDOCARDITIS; HEADACHE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; INSOMNIA; INTERSTITIAL NEPHRITIS; LUNG EDEMA; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYOSITIS; NAUSEA; NONHUMAN; OSTEOMYELITIS; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PNEUMONIA; PREDICTION; RASH; RECURRENT INFECTION; REINFECTION; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; TOE GANGRENE;

EID: 45949109530     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.04.1191268     Document Type: Article

References (42)

1. Ishikawa, T., Matsunaga, N., Tawada, H. et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. 42nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Diego) 2002, Abst F-332.
2. Ishikawa, T., Matsunaga, N., Tawada, H. et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003, 11(11): 2427-37.
3. Hashiguchi, S., Ishikawa, T., Iizawa, Y. (Takeda Pharmaceutical Co., Ltd.). Phosphonocephem compound. EP 1310502, JP 2002220395, US 2004023943, US 2005176697, US 6906055, WO 0214333.
4. Hashiguchi, M., Ishikawa, T., Iizawa, Y. (Takeda Pharmaceutical Co., Ltd.). Phosphonocephem derivatives, their preparation method, and use. JP 11255772, JP 2001048893, US 6417175, WO 9932497.
5. Livermore, D.M. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis 2003, 36(Suppl. 1): S11-23.
6. Iizawa, Y., Nagai, J., Ishikawa, T., Hashiguchi, S., Nakao, M., Miyake, A., Okonogi, K. In vitro antimicrobial activity of T-01925, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004, 10(3): 146-56.
7. Iizawa, Y., Nagai, J., Ishikawa, T., Hashiguchi, S., Miyake, A., Nakao, M., Okonogi, K. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: In vitro and in vivo antibacterial activity. 42nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Diego) 2002, Abst F-333.
8. Sader, H.S., Fritsche, T.R., Kaniga, K., Ge, Y., Jones, R.N. Antimicrobial activity and spectrum of PPI-0903M (T-91625), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005, 49(8): 3501-12.
9. Mushtaq, S., Warner, M., Ge, Y., Kaniga, K., Livermore, D.M. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007, 60(2): 300-11.
10. Ge, Y., Thye, D.A., Talbot, G.H. In vitro activity of ceftaroline against isolates from patients with complicated skin and skin structure infections (cSSSI). 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst C2-864.
11. Kaniga, K., Redman, R., Pecoraro, M.L., Friedland, I., Wikler, M., Ge, Y. Antibacterial activity of PPI-0903 against isolates from patients with complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired pneumonia (HAP). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-1159.
12. Morrissey, I., Curry, J., Ge, Y., Janes, R. The activity of ceftaroline against community-acquired pneumonia (CAP) bloodstream isolates. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst E-281.
13. Jones, R.N., Fritsche, T.R., Ge, Y., Kaniga, K., Sader, H.S. Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005, 56(6): 1047-52.
14. Sader, H.S., Moet, G.J., Fritsche, T.R., Jones, R.N. Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline (PPI-0903M) compared to ceftriaxone against Streptococcus pneumoniae. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst E-121.
15. Schaadt, R., Sweeney, D., Biek, D., Ge, J., Zurenko, G. The in vitro activity of ceftaroline in combination with other antibacterial agents. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst E-279.
16. Jacqueline, C., Caillon, J., Le Mabecque, V. et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007, 51(9): 3397-400.
17. Jacqueline, C., Grossi, O., Le Mabecque, V., Bugnon, D., Cailon, J., Ge, Y., Potel, G. In vivo efficacy of ceftaroline (PPI-0903), a new cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA): Comparison with vancomycin (VAN) and linezolid (LZO) in a rabbit endocarditis model (REM). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst B-1819.
18. Jacqueline, C., Caillon, J., Amador, G. et al. In vivo assessment of the activity of ceftaroline (CPT), linezolid (LZO) and vancomycin (VAN) in a rabbit osteomyelitis experimental model (OEM) due to MRSA and GISA. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst B-1358.
19. Xiong, Y.Q., Li, Y., Abdelsayed, C.A., Biek, D., Bayer, A.S. Real-time evaluation of ceftaroline (CPT), a new cephalosporin vs. vancomycin (VAN) and daptomycin (DAP) in a rat Staphylococcus aureus endocarditis model using in vitro bioluminescent imaging. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst B-819.
20. Ge, Y., Hubbel, A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1935.
21. Jacqueline, C., Caillon, J., Miegeville, A., Launay, E., Batard, E., Ge, Y., Potel, G. Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: Measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1938.
22. Ge, Y., Floren, L., Redman, R., Wikler, M., Liao, S. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1936.
23. Ge, Y., Redman, R., Floren, L., Liao, S., Wikler, M. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1937.
24. Ge, Y., Thye, D., Liao, S., Talbot, G. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1939.
25. Ge, Y., Liao, S., Talbot, G.H. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infection (cSSSI). 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst A-34.
26. Ge, Y., Liao, S., Thye, D.A., Talbot, G.H. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI). 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst A-35.
27. Talbot, G.H., Thye, D., Das, A., Ge, Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007, 51(10): 3612-6.
28. Thye, D., Ge, Y., Das, A., Talbot, G.H. Randomized, observer-blinded, phase 2 study of the efficacy and safety of ceftaroline vs. vancomycin and aztreonam in complicated skin and skin structure infections (cSSSI). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst L-1564c.
29. Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections (NCT00424190). ClinicalTrials.gov Web site, February 29, 2008.
30. Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections (NCT00423657). ClinicalTrials.gov Web site, February 29, 2008.
31. Comparative study of ceftaroline vs. ceftriaxone in adults with community-acquired pneumonia (CAP) (NCT00509106). ClinicalTrials.gov Web site, February 29, 2008.
32. Comparative study of ceftaroline vs. ceftriaxone in adult subjects with community-acquired pneumonia (CAP) (NCT00621504). ClinicalTrials.gov Web site, February 29, 2008.
33. Ge, Y., Biek, D., Sahm, D., Talbot, G.H. In vitro activity of ceftaroline against a collection of recent Gram-positive and Gram- negative U.S. isolates. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst C2-863.
34. Ge, Y., Blosser, R.S., Sahm, D.F., Karlowsky, J.A. In vitro activity of TAK-599, a new anti-MRSA cephalosporin, against Gram-positive and Gram-negative clinical isolates. 104th Gen Meet Am Soc Microbiol (ASM) (May 23-27, New Orleans) 2004, Abst A-139.
35. Brown, S.D., Traczewski, M.M. Ceftaroline: In vitro potency, spectrum of activity, MIC and disk diffusion breakpoints. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst D-239.
36. Mushtaq, S., Warner, M., Kaniga, K., Ge, Y., Livermore, D.M. In vitro activity of cephalosporin PPI-0903M vs. critical resistance types. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-1451.
37. Sader, H.S., Deshpande, L.M., Jones, R.N. Antimicrobial activity and spectrum of PPI-0903 (TAK-599), a novel cephalosporin, tested against a worldwide collection of clinical strains. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst F-325.
38. Sader, H.S., Rhomberg, P.R., Jones, R.N. Evaluation of PPI-0903 (TAK-599), a novel cephalosporin: Bactericidal activity, effects of modifying testing parameters and optimization of disk diffusion tests. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst F-334.
39. Sader, H.S., Fritsche, T.R., Jones, R.N. Antimicrobial activity of ME1036 and ceftaroline tested against clinical strains of community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA). 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst E-280.
40. McGee, L., Biek, D., Ge, Y. et al. Evaluation of the bactericidal activity of ceftaroline (CPT) and ME1036 compared to other beta-lactam agents against cephalosporin-resistant clinical isolates of Streptococcus pneumoniae and R6 mutants with defined resistance genes. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst C2-215.
41. Andes, D.R., Craig, W.A. In vivo pharmacodynamic activity of PPI-0903: A new cephalosporin against multiple bacteria in murine thigh and lung infection models. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst A-1870.
42. Andes, D., Craig, W.A. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: Identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006, 50(4): 1376-83.